Condition: Diabetic Retinopathy (DR) · Sponsor: Ain Shams University
N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability. It was reported in the literature that NAC administration was safe in several studies. It was shown that the dose of 1200 mg is safe and effective. To the best of our knowledge, the present study is the first to be designed to evaluate the effect of N-acetyl cysteine on diabetic retinopathy in type 2 diabetic patients.
This description comes directly from the study's public registry record.
Nelly tarek Hegazy · 01010008548 · nelly.tariq@pharma.asu.edu.eg
Lamiaa Elwakeel, Professor
Always discuss trial participation with your own doctor first.
| National Institute of Diabetes and Endocrinology. | Cairo, Egypt | Recruiting |
| National Institute of Diabetes and Endocrinology. | Cairo, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07634991